A Phase 2 study of a combination tablet formulation of ML-007 and muscarinic antagonist

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ML 007/muscarinic antagonist (Primary)
Indications Alzheimer's disease; Dyskinesias; Psychotic disorders; Schizophrenia
Focus Therapeutic Use

02 Dec 2024 According to a MapLight Therapeutics media release, company plans to initiate Phase 2 trials of ML-007/PAC in schizophrenia and Alzheimer's disease psychosis (ADP) in the first half of 2025.
30 Aug 2023 New trial record
24 Aug 2023 According to a MapLight Therapeutics media release, company plans to advance a fixed-dose, extended-release combination tablet formulation of ML-007 and muscarinic antagonist to Phase 2 studies in 2024, with twice-daily dosing across age groups in those studies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com